SG11201400526TA - Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells - Google Patents
Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cellsInfo
- Publication number
- SG11201400526TA SG11201400526TA SG11201400526TA SG11201400526TA SG11201400526TA SG 11201400526T A SG11201400526T A SG 11201400526TA SG 11201400526T A SG11201400526T A SG 11201400526TA SG 11201400526T A SG11201400526T A SG 11201400526TA SG 11201400526T A SG11201400526T A SG 11201400526TA
- Authority
- SG
- Singapore
- Prior art keywords
- stem cells
- antagonists
- proliferation
- differentiation
- inhibition
- Prior art date
Links
- 210000000130 stem cell Anatomy 0.000 title 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000018109 developmental process Effects 0.000 title 1
- 230000004069 differentiation Effects 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000035755 proliferation Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161533545P | 2011-09-12 | 2011-09-12 | |
| PCT/US2012/054567 WO2013039859A1 (en) | 2011-09-12 | 2012-09-11 | Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201400526TA true SG11201400526TA (en) | 2014-04-28 |
Family
ID=47830014
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201400526TA SG11201400526TA (en) | 2011-09-12 | 2012-09-11 | Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells |
| SG10201601917XA SG10201601917XA (en) | 2011-09-12 | 2012-09-11 | Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201601917XA SG10201601917XA (en) | 2011-09-12 | 2012-09-11 | Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20130064814A1 (en) |
| EP (1) | EP2755674A4 (en) |
| JP (1) | JP2014526475A (en) |
| KR (1) | KR20140084034A (en) |
| CN (1) | CN103957923B (en) |
| AU (1) | AU2012309800B2 (en) |
| CA (1) | CA2848311A1 (en) |
| HK (1) | HK1200120A1 (en) |
| IL (1) | IL231385A0 (en) |
| MX (1) | MX2014002967A (en) |
| SG (2) | SG11201400526TA (en) |
| WO (1) | WO2013039859A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9427429B2 (en) | 2010-03-01 | 2016-08-30 | Tau Therapeutics Llc | Cancer diagnosis and imaging |
| JP2017031059A (en) * | 2014-01-29 | 2017-02-09 | 学校法人慶應義塾 | Cancer stem cell growth inhibitor and intracellular active oxygen accumulation inducer |
| JP6876502B2 (en) * | 2016-04-25 | 2021-05-26 | クラシエホールディングス株式会社 | Undifferentiated cell remover |
| UY37341A (en) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | FORMULATIONS OF GAMMA-MODIFIED RELEASE HYDROXIBUTIRATE WITH IMPROVED PHARMACOCINETICS |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11548925B2 (en) | 2016-09-30 | 2023-01-10 | Genoimmune Therapeutics Co., Ltd. | CACNA1H-derived tumor antigen polypeptide and use thereof |
| WO2019103578A1 (en) * | 2017-11-27 | 2019-05-31 | (주)프로스테믹스 | Oligonucleotide and pharmaceutical composition comprising same for prevention or treatment of cancer |
| CN113473980A (en) | 2019-03-01 | 2021-10-01 | 弗拉梅尔爱尔兰有限公司 | Gamma-hydroxybutyrate compositions with improved pharmacokinetics in fed state |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
| BR9707529A (en) | 1996-02-14 | 2000-01-04 | Isis Pharmaceuticals Inc | Oligunucleotide specifically hybridized with DNA or RNA. |
| US6251886B1 (en) * | 1998-12-07 | 2001-06-26 | Schering Corporation | Methods of using temozolomide in the treatment of cancers |
| ZA200305980B (en) * | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
| NZ533126A (en) | 2002-01-17 | 2006-04-28 | Univ British Columbia | Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same |
| JP2008501633A (en) * | 2004-02-11 | 2008-01-24 | ユニバーシティ オブ ヴァージニア パテント ファウンデーション | Inhibition of the Cav3 isoform and its δ25 splice variant for the diagnosis and treatment of cancer |
| US7662240B2 (en) * | 2004-06-22 | 2010-02-16 | The Timken Company | Seal for worm gear speed reducer |
| KR100743255B1 (en) * | 2006-05-04 | 2007-07-27 | 한국과학기술연구원 | Novel 1,3-dioxoisoindole derivatives having selective antagonism of t-type calcium channel |
| TW200831538A (en) * | 2006-12-19 | 2008-08-01 | Genentech Inc | VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
| WO2009036099A1 (en) * | 2007-09-10 | 2009-03-19 | Boston Biomedical, Inc. | A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors |
| PL2307459T3 (en) * | 2008-07-08 | 2015-05-29 | Oncomed Pharm Inc | Notch1 receptor binding agents and methods of use thereof |
| US20120088807A1 (en) * | 2009-06-05 | 2012-04-12 | Tau Therapeutics Llc | Interlaced method for treating cancer or a precancerous condition |
-
2012
- 2012-09-11 AU AU2012309800A patent/AU2012309800B2/en not_active Ceased
- 2012-09-11 JP JP2014529965A patent/JP2014526475A/en active Pending
- 2012-09-11 MX MX2014002967A patent/MX2014002967A/en unknown
- 2012-09-11 CA CA2848311A patent/CA2848311A1/en not_active Abandoned
- 2012-09-11 CN CN201280055308.5A patent/CN103957923B/en not_active Expired - Fee Related
- 2012-09-11 WO PCT/US2012/054567 patent/WO2013039859A1/en active Application Filing
- 2012-09-11 US US13/609,942 patent/US20130064814A1/en not_active Abandoned
- 2012-09-11 EP EP12832679.0A patent/EP2755674A4/en not_active Withdrawn
- 2012-09-11 SG SG11201400526TA patent/SG11201400526TA/en unknown
- 2012-09-11 SG SG10201601917XA patent/SG10201601917XA/en unknown
- 2012-09-11 KR KR1020147009726A patent/KR20140084034A/en not_active Application Discontinuation
-
2014
- 2014-03-06 IL IL231385A patent/IL231385A0/en unknown
-
2015
- 2015-01-21 HK HK15100687.1A patent/HK1200120A1/en unknown
-
2019
- 2019-11-15 US US16/685,279 patent/US20200197516A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20130064814A1 (en) | 2013-03-14 |
| MX2014002967A (en) | 2015-04-13 |
| AU2012309800A1 (en) | 2014-05-01 |
| JP2014526475A (en) | 2014-10-06 |
| CN103957923B (en) | 2018-05-25 |
| HK1200120A1 (en) | 2015-07-31 |
| EP2755674A1 (en) | 2014-07-23 |
| SG10201601917XA (en) | 2016-04-28 |
| CN103957923A (en) | 2014-07-30 |
| CA2848311A1 (en) | 2013-03-21 |
| AU2012309800B2 (en) | 2017-10-05 |
| IL231385A0 (en) | 2014-04-30 |
| US20200197516A1 (en) | 2020-06-25 |
| KR20140084034A (en) | 2014-07-04 |
| EP2755674A4 (en) | 2015-04-08 |
| WO2013039859A1 (en) | 2013-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1200120A1 (en) | Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells hs.459642 | |
| ZA201107806B (en) | Organisms for the production of 1,3-butanediol | |
| EP2705428A4 (en) | Processing, modification, distribution of installation packages | |
| PL3141552T3 (en) | Thienopyrimidine derivatives having inhibitory activity for protein kinase | |
| PL2620156T3 (en) | Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing stem cells treated with nod2 agonist or cultured product thereof | |
| AP2011005978A0 (en) | 2, 4 diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation. | |
| EP2632260A4 (en) | Leucine-rich repeat kinase enzyme activity | |
| MY154507A (en) | Gene Controlling Shell Phenotype in Palm | |
| HK1209277A1 (en) | 1,2,4-triazine-6-carboxamide kinase inhibitors 124--6- | |
| EP2576488A4 (en) | Process for cis-1,1,1,4,4,4,-hexafluoro-2-butene | |
| IN2014CN04050A (en) | ||
| PL2366517T3 (en) | Machine for the production of ceramic products. | |
| MY165218A (en) | Method for preparation of medetomidine with chloroacetone | |
| TN2013000201A1 (en) | Methods and compositions for drying coal | |
| HK1191693A1 (en) | Assay for screening compounds that selectively decrease the numer of cancer stem cells | |
| WO2012090073A3 (en) | Methods and compositions for predicting chemotherapy sensitivity | |
| WO2014124155A3 (en) | Methods for inducing cardiomyocyte proliferation | |
| WO2013032960A3 (en) | Vitamin d receptor - coregulator inhibitors | |
| WO2013025939A9 (en) | Compounds and methods for treating cancer by inhibiting the urokinase receptor | |
| WO2012112156A3 (en) | Compositions useful for cancer detection and treatment, a cancer stem cell model, and methods of production and use thereof | |
| EP2409156A4 (en) | Akt tyrosine 176 phosphorylation cancer biomarker | |
| MX2013011184A (en) | Compositions and methods for treating, diagnosing and monitoring disease. | |
| FR2974277B1 (en) | PROCESS FOR PREPARING CEREAL GRAIN, PREPARATION FACILITY AND CORRESPONDING CEREAL GRAIN | |
| IT1400887B1 (en) | PROCEDURE AND PLANT FOR LEATHER COATING. | |
| PL398104A1 (en) | Method for obtaining the hydrolyzate, with ACE enzyme inhibitory properties |